Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial

RCT (n=308) found that compared with existing services, combined pharmacological (380mg extended-release naltrexone) and behavioural harm-reduction treatment resulted in decreased alcohol use and alcohol-related harm during the 12-week treatment period.

The Lancet Psychiatry